MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Aziyo Biologics Cost of Revenue 2011-2026 | AZYO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Aziyo Biologics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.7 M | 12.2 M | 28.4 M | 22.1 M | 23.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28.4 M | 12.2 M | 19.9 M |
Quarterly Cost of Revenue Aziyo Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.47 M | 3.2 M | 3.57 M | 1.87 M | 3.49 M | 3.85 M | 3.29 M | 3.64 M | 3.02 M | - | 2.91 M | 7.74 M | 7.21 M | - | 7.8 M | 6.55 M | 6.56 M | - | 6.23 M | 4.8 M | 4.65 M | - | 5.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.8 M | 1.47 M | 4.6 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.11 | -10.77 % | $ 260 M |  USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 13.94 | -0.71 % | $ 2.09 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 7.0 | 5.74 % | $ 503 M |  Israel |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.38 | -4.58 % | $ 163 M |  France |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.49 | 2.05 % | $ 121 M | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 31.87 | 2.07 % | $ 1.47 B | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 275.33 | 2.19 % | $ 7.77 B | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 40.88 | 2.48 % | $ 6.09 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 75.65 | 2.97 % | $ 112 B | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 14.0 | 0.29 % | $ 905 M | Israel |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 14.09 | -7.06 % | $ 381 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 45.89 | -0.18 % | $ 1.42 B | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.48 | 1.02 % | $ 146 M | Israel |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.18 | 1.09 % | $ 204 M | USA |
 |
Establishment Labs Holdings
ESTA
|
56.5 M | $ 77.41 | -1.12 % | $ 2.18 B |  Costa-rica |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 96.27 | 0.06 % | $ 13 B | USA |
 |
Tandem Diabetes Care
TNDM
|
469 M | $ 26.14 | 0.5 % | $ 1.78 B | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.11 | -2.76 % | $ 1.28 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 11.13 | -4.01 % | $ 857 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.73 | 2.57 % | $ 39.7 M | USA |
 |
Inogen
INGN
|
181 M | $ 6.4 | 6.53 % | $ 151 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.47 | -2.0 % | $ 23.7 M | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 102.4 | 1.89 % | $ 1.3 B | USA |